Cantourage Group SE
Cantourage Group SE operates in the drug retailing industry, providing pharmaceutical and healthcare products to consumers.
Business. Cantourage Group SE (HIGHG.DE) is a drug retailer operating within the Food & Drug Retailing industry. The company is headquartered in Germany and is primarily listed on the Xetra exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Cantourage Group SE (HIGHG.DE) is a drug retailer operating within the Food & Drug Retailing industry. The company is headquartered in Germany and is primarily listed on the Xetra exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Cantourage Group SE has a basic and diluted share count of 11,875,000 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available for Cantourage Group SE, as the valuation snapshot does not include key financial ratios such as ROIC, EBITDA margins, or net profit margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians.
The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is unclear whether Cantourage Group SE is exposed to specific regional or product-line risks that could impact its financial stability.
Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or revenue history. Analysts have assigned a mean price target of 9.00 EUR, with a median of 9.00 EUR, suggesting a neutral to slightly bullish sentiment. The mean recommendation of 1.50 (on a 1-5 scale) indicates a generally positive outlook, with one strong-buy and one buy recommendation.
Risk factors include the inability to assess liquidity risk, which could pose a challenge if the company faces unexpected cash flow pressures. The dilution risk is currently low, but this could change if the company issues additional shares in the future. No adjustments have been applied to the valuation metrics, and no specific risk factors are disclosed in the available data.
Recent events, such as filings or transcripts, are not included in the available data. Analysts have provided price targets and recommendations, but no recent corporate actions or strategic developments are disclosed.
- Cantourage Group SE operates in the drug retailing industry with a focus on pharmaceutical and healthcare products.
- The company has no immediate dilution pressure, with basic and diluted shares outstanding being equal.
- Analysts have assigned a neutral to slightly bullish outlook, with a mean price target of 9.00 EUR.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
- Profitability and return metrics are not available, making it difficult to compare the company against industry benchmarks.
- Revenue concentration and geographic exposure are not disclosed, limiting visibility into potential regional or product-line risks.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue €2.2M, +32,1% YoY; Operating income +50,8% YoY.
- ▍Revenue €2.2M, +32,1% YoY
- ▍Operating income +50,8% YoY
- ▍Net income +105,0% YoY
- ▍Net margin 3.6%
Revenue €1.7M, +175,6% YoY; Operating income +171,5% YoY.
- ▍Revenue €1.7M, +175,6% YoY
- ▍Operating income +171,5% YoY
- ▍Net income +329,3% YoY
- ▍Net margin 2.3%
Revenue €603.3k; Operating income €28.7k.
- ▍Revenue €603.3k
- ▍Operating income €28.7k
- ▍Net margin 1.5%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,30 |
| Revenue | —no estimate | —no estimate | 102,7M EUR |
| Operating income | —no estimate | —no estimate | 5,0M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Cantourage Group SE Market data — financials · 2026-05-28
- Cantourage Group SE Market data — analyst estimates · 2026-05-28